Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 12/20 | 0.51 |
| ▸ | CHUK | O15111 | 12/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26671802 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KMT2AKDM4ERECQLSMN1; SMN2 | |
| SCHEMBL2994737 | 0.87 | ALDH1A1 (0.49) | IKBKBCHUKALDH1A1KMT2AKDM4E | |
| SCHEMBL2985529 | 0.84 | ALDH1A1 (0.72) | IKBKBCHUKALDH1A1KMT2AKDM4E | |
| SCHEMBL2991766 | 0.76 | ALDH1A1 (0.65) | IKBKBCHUKALDH1A1KMT2AKDM4E | |
| SCHEMBL14278882 | 0.72 | KDM4E (0.56) | IKBKBCHUKALDH1A1KMT2AKDM4E | |
| SCHEMBL13013467 | 0.72 | ALDH1A1 (0.69) | IKBKBCHUKALDH1A1KMT2AKDM4E | |
| SCHEMBL3415505 | 0.72 | MAPK1 (0.69) | IKBKBCHUKALDH1A1KMT2AKDM4E | |
| SCHEMBL19994965 | 0.71 | KMT2A (0.51) | IKBKBCHUKALDH1A1KMT2AKDM4E | |
| SCHEMBL2985526 | 0.71 | ALDH1A1 (0.71) | IKBKBCHUKALDH1A1KMT2AKDM4E | |
| SCHEMBL17807630 | 0.70 | ALDH1A1 (0.85) | ALDH1A1KMT2AKDM4ERECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | IKBKB 11/4885CHUK 22/4885ALDH1A1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.